


Third Quarter 2022 Results Call

Corporate Update & Financial Results

November 1, 2022



Forward-Looking Statements



BioCryst's presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst's documents filed with the SEC and located at <https://ir.biocryst.com/financial-information/sec-filings>.

Agenda

- ◆ Corporate Update:

Jon Stonehouse – President and Chief Executive Officer

- ◆ ORLADEYO[®] (berotralstat) Launch Update:

Charlie Gayer – Chief Commercial Officer

- ◆ Pipeline Update

Dr. Helen Thackray – Chief Research and Development Officer

- ◆ Financial Update

Anthony Doyle – Chief Financial Officer

- ◆ Summary and Q&A

Our Pipeline



PROGRAM	LEAD OPTIMIZATION	PRECLINICAL	EARLY DEVELOPMENT	PIVOTAL	APPROVED / COMMERCIAL
HEREDITARY ANGIOEDEMA (HAE)					
ORLADEYO® (berotralstat) Oral Plasma Kallikrein Inhibitor	[Progress bar spanning all stages]				
COMPLEMENT-MEDIATED DISEASES					
BCX9930 – Oral Factor D Inhibitor (PNH)	[Progress bar spanning Lead Optimization, Preclinical, Early Development, Pivotal]				
BCX9930 – Oral Factor D Inhibitor (C3G/IgAN/PMN)	[Progress bar spanning Lead Optimization, Preclinical, Early Development]				
BCX10013 – Oral Factor D Inhibitor	[Progress bar spanning Lead Optimization, Preclinical, Early Development]				
Oral Drugs for Complement (Targets Undisclosed)	[Progress bar spanning Lead Optimization]				
INFECTIOUS DISEASES					
RAPIVAB® (peramivir injection)	[Progress bar spanning all stages]				

Finance Summary

(figures in millions)

3Q22 Cash Position

Cash, cash equivalents, restricted cash & investments at September 30, 2021	\$204
Cash, cash equivalents, restricted cash & investments at September 30, 2022	\$463
Senior Credit Facility ^A	\$232

2022 FY Guidance

ORLADEYO Revenue	\$255
Operating Expenses (excluding non-cash comp)	\$365 - \$370

A – From Athyrium Capital Management, term loan of \$200M interest-only for 5-year term, \$32.4 in interest payment-in-kind (PIK) has been added to principal since issuance

Third Quarter 2022 Results Call

Corporate Update & Financial Results

November 1, 2022

